Paradigm Asset Management Co. LLC Has $2.22 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Paradigm Asset Management Co. LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,388 shares of the company’s stock after selling 500 shares during the quarter. Merck & Co., Inc. comprises about 0.6% of Paradigm Asset Management Co. LLC’s portfolio, making the stock its 29th biggest position. Paradigm Asset Management Co. LLC’s holdings in Merck & Co., Inc. were worth $2,223,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bare Financial Services Inc acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $28,000. Rakuten Securities Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $30,000. RIA Advisory Group LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $30,000. Tidemark LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $31,000. Finally, AlphaMark Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $34,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of MRK stock traded down $1.60 during trading on Monday, hitting $129.49. The company’s stock had a trading volume of 5,983,800 shares, compared to its average volume of 7,980,648. The company has a market cap of $327.97 billion, a PE ratio of 143.88, a P/E/G ratio of 1.66 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The business has a fifty day moving average of $128.15 and a 200-day moving average of $119.79. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. Merck & Co., Inc.’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.40 earnings per share. As a group, research analysts anticipate that Merck & Co., Inc. will post 8.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on MRK shares. Societe Generale downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a research note on Monday, March 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. UBS Group boosted their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Finally, TheStreet lowered Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $131.33.

Check Out Our Latest Stock Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.